These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2331124)

  • 1. Median incubation time for human immunodeficiency virus (HIV).
    Winkelstein W; Royce RA; Sheppard HW
    Ann Intern Med; 1990 May; 112(10):797-8. PubMed ID: 2331124
    [No Abstract]   [Full Text] [Related]  

  • 2. Research. 'Superinfected' have more potent antibody response to HIV.
    AIDS Policy Law; 2012 May; 27(6):3. PubMed ID: 22655314
    [No Abstract]   [Full Text] [Related]  

  • 3. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development.
    Neurath AR; Strick N; Taylor P; Rubinstein P; Stevens CE
    AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1183-92. PubMed ID: 1701315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-induced HIV seropositivity: a problem on the rise.
    Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
    J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgM antibodies directed to HIV: the neglected issue?
    Van de Perre P; Desgranges C; Burny A
    AIDS Res Hum Retroviruses; 1994 May; 10(5):517-20. PubMed ID: 7917512
    [No Abstract]   [Full Text] [Related]  

  • 6. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
    Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
    AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody in human immunodeficiency virus infection.
    Brunell PA
    Ann N Y Acad Sci; 1993 Oct; 693():9-13. PubMed ID: 8267297
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lack of detectable HIV-1 antibody in a person with HIV infection--Utah, 1995.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Mar; 45(9):181-5. PubMed ID: 8604214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men: a report from the Multicenter AIDS Cohort Study.
    Dis Markers; 1989; 7(4):257-8. PubMed ID: 2684476
    [No Abstract]   [Full Text] [Related]  

  • 12. [Silent HIV infection in HIV seronegative individuals?].
    Waldum HL; Iversen OJ
    Tidsskr Nor Laegeforen; 1990 Mar; 110(8):997-8. PubMed ID: 2181734
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2.
    Ng KP; Saw TL; Baki A; He J; Singh N; Lyles CM
    Int J STD AIDS; 1999 Jun; 10(6):401-4. PubMed ID: 10414883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL; Barouch DH; Montefiori DC
    Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibody response to the HIV-1 specific "out" (vpu) protein: identification of an immunodominant epitope and correlation of antibody detectability to clinical stages.
    Schneider T; Hildebrandt P; Rönspeck W; Weigelt W; Pauli G
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):943-50. PubMed ID: 1697179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Jun; 5(3):347-63. PubMed ID: 16827619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL; Williamson C; Morris L
    Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1.
    Lathey JL; Pratt RD; Spector SA
    J Infect Dis; 1997 Jan; 175(1):231-2. PubMed ID: 8985228
    [No Abstract]   [Full Text] [Related]  

  • 20. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.
    Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM
    Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.